2. Vías de señalización
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. CA VA Isoform

CA VA

CA VA (CAVA/CA5A) is a mitochondrial carbonic anhydrase that catalyzes CO2 hydration to supply HCO3- for mitochondrial metabolism[1]. Mechanistically, CA VA supports ureagenesis, gluconeogenesis, and lipogenesis by providing bicarbonate to liver metabolic enzymes[1][2]. In disease models, CA5A mutations reduce CAVA activity or thermal stability and cause early-onset metabolic crisis with hyperammonemia, hyperlactatemia, ketonuria, metabolic acidosis, and hypoglycemia[3][4]. Compared with CA VB, CA VA has the predominant liver role in ammonia detoxification, while CA VB contributes more clearly when CA VA is absent[1][2]. For experimental applications, recombinant CAVA expression and purification support biochemical studies, and selective mitochondrial CA VA/VB inhibitors provide tools to study metabolism-linked pathways[5][6].

Productos relacionados con CA VA (2):

Cat. No. Nombre del producto Efecto Pureza
  • HY-109056
    Elsulfavirine
    		Inhibitor 99.90%
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
  • HY-109056A
    Elsulfavirine sodium
    		Inhibitor
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.